ReviewCells2026
Exosomes and Extracellular Vesicles in Oncology: Next-Generation Smart Nanocarriers for Precision Cancer Therapy.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are an evolved sub-type of extracellular vesicles (EVs) that have gained popularity in recent years as a novel biological nanocarrier system for targeted precision therapy in cancer owing to their excellent biocompatibility, low immunogenicity, and high stability. While other artificial systems can only deliver specific types of drug, exosomes have been found to effectively carry different types of therapeutic cargo, such as chemotherapeutic agents, proteins, peptides, mRNA, siRNA, miRNA, and even CRISPR/Cas gene editing elements. Recent progress in exosome engineering technologies, such as surface modification, donor cell modification, bionic hybrid vesicles, and stimuli-responsive exosomes, has improved their targeting efficacy, cargo-loading capacity, and controlled drug release properties. Apart from their therapeutic use, exosomes play an active role in promoting tumor development by regulating the tumor microenvironment, angiogenesis, metastasis, immune escape, maintenance of cancer stem cells, and drug resistance. This review provides a brief insight into the biological properties of exosomes, recent developments in isolation and characterization methods, engineering approaches, therapeutic cargo loading, and their uses in targeted chemotherapy, gene and RNA therapy, immunotherapy, phototherapy, sonodynamic therapy, chemo-dynamic therapy, and combinational therapy. Moreover, the existing issues in exosome research, such as exosome heterogeneity, large-scale production, quality control, and regulatory issues, are addressed. Finally, new approaches involving artificial intelligence, multi-omics technology, and personalized engineering of exosomes are presented as potential solutions to enhance the clinical use of exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.